When compared with TKI responders, CML patients with inadequate response had significantly higher expressions of LN989, PROX1-AS1, SENCR, LN892, and KIF25-AS1 (Fig. 3C). The gene discussed is PROX1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.